MODERN ISSUES OF HEMOLYTIC DISEASE OF NEWBORNS. RISK FACTORS AND CLINICAL OPTIONS
Abstract
The review article, based on modern domestic and foreign literature, analyzes the issues of hemolytic disease of newborns from the perspective of identifying risk factors and clinical course. The issues of classification are covered in detail depending on the type of serological conflict, the predominance of the main clinical syndrome, the degree of severity, timing of occurrence, period, damage to organs and systems, and the accompanying unfavorable background. Among a number of risk factors for the development of complications in GDN are prematurity, severe asphyxia, hypoglycemia, hypoalbuminemia, and dyselectrolythemia. In all of the listed pathogenetic processes of the formation of clinical variants and complications of GDN, changes in the metabolic status are also involved in a certain way, and among these changes, hypoalbuminemia, hypoglycemia, and dyselectrolythemia are again distinguished, which characterizes the characteristics of the body’s resistance, in particular, the special reactivity of the central
nervous system is distinguished
About the Authors
List of references
Volodina N.N., Degtyareva D.N., Kryuchko D.S. Clinical recommendations. Hemolytic disease of newborns. M:GEOTAR-Media 2019.
Korochanskaya S.P., Khvostova T.S. Biochemical features of metabolism in children. Textbook for university 2023.
Volodina N.N. Neonatology: National Guide. M: GEOTAR-Media 2013:896.
Venkataraman R, Yusuf K. Intravenous immunoglobulin in the management of a rare cause of hemolytic disease of the newborn: anti-SARA antibodies. J Neonatal Perinatal Med 2017;10:329–32. DOI: https://doi.org/10.3233/NPM-16131
Baibarina E.N., Degtyareva D.N. Selected clinical recommendations for neonatology. M: GEOTAR-Media 2016:237.
Delaney M., Matthews D. C. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program 2015;20:146–51. DOI: https://doi.org/10.1182/asheducation-2015.1.146
Moise KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132–9. https://doi.org/10.1097/aog.0b013e31826d7dc1. DOI: https://doi.org/10.1097/AOG.0b013e31826d7dc1
Palchik A. B., Shabalov N. P. Toxic encephalopathies of newborns. 2nd ed, rev And additional – M: MEDpress-inform 2012:176.
Shabalov N.P. Neonatology: Textbook: in 2 volumes. M: GEOTAR-Media 2013.
Volodin N. N., Degtyarev D. N., Kryuchko D. S. Neonatology. clinical recommendations. M: GOETAR-Media 2019.
Savelyeva G.M., Adamyan L.V., Kurtser M.A., Sichinava L.G. Rhesus sensitization. Hemolytic disease of the fetus. Clinical guidelines (protocol) 2017:16.
Feldman AG, Sokol RJ. Neonatal Cholestasis. NeoReviews 2013;14. https://doi.org/10.1542/neo.14-2-e63. DOI: https://doi.org/10.1542/neo.14-2-e63
Zipursky A., Butani V.K. Diagnosis and treatment of hemolytic disease of newborns. Clinical recommendations. M: GOETAR-Media 2015;386:651. DOI: https://doi.org/10.1016/S0140-6736(15)61498-2
Savelyeva G. M, Sukhikh G. T, Serov V. N, Radzinsky V. E. Obstetrics: national guide 2015:1080.
Katz S. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. Pediatr Emerg Care 2011;27:162–3. https://doi.org/10.1097/PEC.0b013e31820a261e. DOI: https://doi.org/10.1097/PEC.0b013e31820a261e
Nandyal R. Hemolytic Disease of the Newborn. J Hematol Thromboembolic Dis 2015;03. https://doi.org/10.4172/2329-8790.1000203. DOI: https://doi.org/10.4172/2329-8790.1000203
Raguz MJ, Prce Z, Bjelanovic V, Bjelanovic I, Dzida S, Mabic M. 20 Years of Follow-up Alloimmunization and Hemolytic Disease in Newborn: Has Anything Changed in the Field Over the Years? Klin Padiatr 2020;232:314–20. https://doi.org/10.1055/a-1248-2329. DOI: https://doi.org/10.1055/a-1248-2329
Palchik A.B, Shabalov N.P. Hypoxic-ischemic encephalopathy of newborns. M MEDpress-inform 3rd ed, revised 2011:272.
Volodin N.N. Tactics for the management of full-term and premature newborns with indirect hyperbilirubinemia. Clinical recommendations 2017.
Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol Off J Calif Perinat Assoc 2012;32:660–4. https://doi.org/10.1038/jp.2012.71. DOI: https://doi.org/10.1038/jp.2012.71
Djumakulov F. Immunological changes in a fetus with hemolytic disease during rhesus-immunization of the mother. European Journal of Molecular and Clinical Medicine 2020;7:1548–58.
Cruz-Leal Y. Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models. Current Opinion in Hematology 2017;24:536–43. DOI: https://doi.org/10.1097/MOH.0000000000000374
Fasano R.M. Hemolytic disease of the fetus and newborn in the molecular era. Seminars In Fetal & Neonatal Medicine 2015. DOI: https://doi.org/10.1016/j.siny.2015.10.006
Isakhanov M. A., Sharipova M. G., Manabaeva G. K. Prevention and non-invasive diagnosis of hemolytic disease of the fetus. electronic scientific journal UNIVERSUM: medicine and pharmacology 2019.
Vasilevsky I.V. Clinical pharmacology and pediatric practice. Medical news 2014:6–12.
Avrutskaya V.V., Gimbut V.S., Khloponin A.V., Orlov A.V. Modern principles of management of Rh-conflict pregnancy. Problems of women’s health 2015;10:40–4.
Ivanova A.V., Zakharova S.Yu., Pestryaeva L.A. Features of erythrocyte morphology in children with hemolytic disease of newborns who have undergone intrauterine, intravascular blood transfusion. Russian Bulletin of Perinatology and Pediatrics 2016. DOI: https://doi.org/10.21508/1027-4065-2016-61-1-42-45
Volodin N.N. Hemolytic disease of the fetus and newborn: diagnosis, treatment, prevention: textbook. Moscow: RNIMU im NI Pirogova 2020:92.
Haider M, Memon S, Tariq F, Fatima S, Hameed A. Rhesus Isoimmunization: Late-onset Hemolytic Disease of the Newborn Without Jaundice. Cureus 2020;12:e6559. https://doi.org/10.7759/cureus.6559. DOI: https://doi.org/10.7759/cureus.6559
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
